Patents Issued in November 7, 2017
  • Patent number: 9809616
    Abstract: The compounds are of the class of N4-hydroxycytidine nucleosides, modified monophosphate and phosphonates prodrugs analogs, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof, useful in treating HCV or Norovirus infections.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: November 7, 2017
    Assignees: Emory University, Cocrystal Pharma, Inc.
    Inventors: Franck Amblard, Steven J. Coats, Raymond F. Schinazi
  • Patent number: 9809617
    Abstract: The present invention relates to the field of medicinal chemistry, and discloses a new crystal form of regadenoson, i.e., a crystal form E of regadenoson, as well as a method for preparing the new crystal form of regadenoson. The crystal form E of regadenoson according to the present invention has excellent performances in terms of radionuclide myocardial perfusion imaging, and has a poor toxicity, good storage stability, and can be used in the preparation of a medicament used as a stress agent for radionuclide myocardial perfusion imaging.
    Type: Grant
    Filed: July 3, 2015
    Date of Patent: November 7, 2017
    Assignee: Shanghai Ziyuan Pharmaceutical Co., Ltd.
    Inventors: Wei Liu, Zhigang Zhang, Qin Bao
  • Patent number: 9809618
    Abstract: A new process for enriching triterpene esters comprising: providing a mixture comprising a non-distilled vegetable oil and/or a non-distilled vegetable fat, further comprising triterpene esters, performing a mild transesterification with a lower alcohol, removing lower alcohol esters by deodorization, physical refining, evaporation or distillation, and recovering the remaining fraction rich in triterpene esters. Triterpene esters enriched with the method as well as uses of the same are also provided. One advantage is that it is a more economically viable way of achieving higher concentration of triterpene esters. There is both the chance to fully keep the natural distribution of triterpene esters but in the other end also to replace the natural level of cinnamic and acetic acids-triterpene esters with a high level of long fatty acid triterpene-esters.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: November 7, 2017
    Assignee: AAK AB
    Inventors: Jari Alander, Staffan Norberg, Krister Hed
  • Patent number: 9809619
    Abstract: Methods for pulse combustion spray drying of heat-sensitive protein compositions using high temperature pulsating jets to atomize and dry the feed simultaneously are described herein. Methods and compositions described herein provide dried protein-containing compositions with low protein denaturation and other useful functional properties at high operational efficiencies.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: November 7, 2017
    Assignee: PULSE HOLDINGS, LLC
    Inventors: James A. Rehkopf, David A. Mirko
  • Patent number: 9809620
    Abstract: Prion peptides comprising prion epitopes and fusions thereof, that display enhanced immunogenicity are described. Also described are methods of treating and diagnosing prion disease.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: November 7, 2017
    Assignee: University of Saskatchewan
    Inventors: Kristen Marciniuk, Ryan Taschuk, Scott Napper, Andrew Potter, Neil Cashman
  • Patent number: 9809621
    Abstract: It is provided PACE4 inhibitors and their uses for treating infection, cancer. Particularly, it is provided a method or use for the treatment of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the PACE4 inhibitors or the composition disclosed.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: November 7, 2017
    Assignee: SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C.
    Inventors: Robert Day, Witold A. Neugebauer, Yves Dory
  • Patent number: 9809622
    Abstract: A tumor-targeting peptide is disclosed. This tumor-targeting peptide comprises a typical motif with the general formula of: XX(Y/F) (D/E) (D/E) XX. The motif is selectively connected with 1-3 amino acids at the C-terminal and/or N-erminal. X represents any one of the twenty natural amino acids or the D type amino acids. The present invention also discloses that the peptide can not only target tumor vessels and tumor cells but also penetrate them and thus can be applied in tumor diagnosis and therapy.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: November 7, 2017
    Assignee: Sun Yat-Sen University Cancer Center
    Inventors: Musheng Zeng, Xing Zhang, Jun Wang, Guokai Feng, Mengqing Zhang, Qian Zhong
  • Patent number: 9809623
    Abstract: The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against ?4?1 binding, and have high stability under gastrointestinal conditions.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: November 7, 2017
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Larry C. Mattheakis, David Liu
  • Patent number: 9809624
    Abstract: The invention relates to a new neurotensin analogue, or a salt thereof, useful for targeting to neurotensin receptor-positive tumors, like ductal pancreatic adenocarcinoma, exocrine pancreatic cancer, invasive ductal breast cancers, colon adenocarcinoma, small cell lung carcinoma, Ewing sarcoma, meningioma, medulloblastoma and astrocytoma.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: November 7, 2017
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), IASON GmbH
    Inventors: Anne Gruaz, Didier Pelaprat, Jacques Barbet, Dirk Tourwe
  • Patent number: 9809625
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: November 7, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Paul Michael Scola
  • Patent number: 9809626
    Abstract: The invention provides compounds of formula (I): and salts thereof, wherein X and Y have any of the values defined herein. The compounds inhibit bacterial RNA polymerase, inhibit bacterial growth, and have applications in, analysis of RNA polymerase structure and function, control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, antibacterial therapy, and drug discovery.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: November 7, 2017
    Assignee: Rutgers, the State University of New Jersey
    Inventors: Richard H. Ebright, Yon W. Ebright, Yu Feng, David Degen
  • Patent number: 9809627
    Abstract: The present disclosure describes cyclized peptides that inhibit A? toxicity and therefore can be used as therapeutic agents to treat Alzheimer's Disease.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: November 7, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Regina M. Murphy, Patricia Y. Cho, Jeffrey A. Johnson, Xiaomeng Lu
  • Patent number: 9809628
    Abstract: The present invention refers to methods for selectively recognizing a base pair in a DNA sequence by a polypeptide, to modified polypeptides which specifically recognize one or more base pairs in a DNA sequence and, to DNA which is modified so that it can be specifically recognized by a polypeptide and to uses of the polypeptide and DNA in specific DNA targeting as well as to methods of modulating expression of target genes in a cell.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: November 7, 2017
    Inventors: Ulla Bonas, Jens Boch, Sebastian Schornack, Thomas Lahaye
  • Patent number: 9809629
    Abstract: Disclosed are hypoallergenic variants of Phl p 5, the major allergen from Phleum pratense, and the uses thereof in the treatment of allergic diseases.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: November 7, 2017
    Assignee: LOFARMA S.P.A.
    Inventors: Giovanni Mistrello, Stefania Zanotta, Daniela Roncarolo
  • Patent number: 9809630
    Abstract: The present invention is directed to enzyme based methods for separating protein from protein-rich materials derived from plant seeds, fruit, or other biomass and products made therefrom. The protein content in the resulting products is improved by separating and removing the carbohydrates from around the proteins in, for example, soybean meal. This removal is facilitated by the enzymatic hydrolysis of poly- and oligomeric carbohydrates into monosaccharides and other water soluble sugars. The present invention provides for the production of three streams of useful materials. The first is an enriched protein material comparable to the known SPCs but without significant quantities of undigestible oligosaccharides and polysaccharides. The second is an SPI made from the soluble protein in the hydrolysate which is valuable for high-quality feed, food and industrial uses.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: November 7, 2017
    Assignee: THE UNIVERSITY OF AKRON
    Inventors: Lu-Kwang Ju, Abdullah Loman, Anthony Coffman, Qian Li, Srujana Koganti
  • Patent number: 9809631
    Abstract: Lectin compositions and methods for reducing tumor cell growth and preventing or treating cancer are provided.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: November 7, 2017
    Inventors: Gary S. Goldberg, Yongquan Shen
  • Patent number: 9809632
    Abstract: Disclosed herein are chimeric proteins that include one or more double stranded nucleic acid binding domains (dsNABD) and one or more polyHis domains, and compositions that further include a therapeutic double stranded nucleic acid and a targeting ligand bound to the therapeutic double stranded nucleic acid, wherein the dsNABD of the chimeric protein is bound to the therapeutic double stranded nucleic acid, and uses of the compositions to treat disease.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: November 7, 2017
    Assignee: University of Washington Through its Center for Commercialization
    Inventors: Xiaohu Gao, Hong Yan Liu
  • Patent number: 9809633
    Abstract: Peptide-based reagents, compositions and oral care products containing the peptide-based reagents, and methods for using the peptide-based reagents, compositions, or oral care products to treat dental diseases such as periodontitis, tooth erosion, hypersensitivity, bacterial plaque, dental fluorosis, tooth decay, carries, tooth resorption, and gingival recession, are described.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: November 7, 2017
    Assignee: University of Washington Through its Center for Commercialization
    Inventors: Mehmet Sarikaya, Martha Somerman, Candan Tamerler-Behar, Hanson Fong, Hai Zhang, Mustafa Gungormus
  • Patent number: 9809634
    Abstract: Provided are a branched multi-peptide composition and a vaccine including the same. The branched multi-peptide vaccine according to the present invention is easy to be produced and utilized, thereby being easily applied to the treatment, and is capable of maintaining stable reaction in vivo, such that it is expected that the branched multi-peptide vaccine according to the present invention acts as an effective vaccine. Further, for the tumor antigen peptide, the present invention may select an antigen that is largely expressed in a malignant brain tumor. In addition, from now on, it is expected that tumor antigens having a large expression level may be analyzed depending on tumor characteristics of an individual patient, such that the branched multi-peptide vaccine according to the present invention may be utilized for producing personalized branched peptides and vaccines using the same.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: November 7, 2017
    Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
    Inventors: Tae-Young Jung, Young-Hee Kim
  • Patent number: 9809635
    Abstract: The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: November 7, 2017
    Assignee: LifeNet Health
    Inventors: Xiaofei Qin, Silvia Chen, Jingsong Chen, James A. Clagett
  • Patent number: 9809636
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: November 7, 2017
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani, John Knopf
  • Patent number: 9809637
    Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: November 7, 2017
    Assignee: ACCLERON PHARMA INC.
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
  • Patent number: 9809638
    Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: November 7, 2017
    Assignee: Amgen Inc.
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
  • Patent number: 9809639
    Abstract: Materials and methods for use of constrained cohydration agents in the purification of biological materials such as antibodies, viruses, cells, and cellular organelles in connection with convective chromatography, fluidized bed or co-precipitation applications.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: November 7, 2017
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventor: Peter Stanley Gagnon
  • Patent number: 9809640
    Abstract: The present invention provides novel pharmaceutical compositions comprising ApoE-derived peptide dimers. In particular, the ApoE peptide dimers of the invention comprise at least two ApoE mimetic domains and can comprise one or more protein transduction domains. Methods of treating various conditions, such as cancer, inflammatory conditions, and neurodegenerative diseases, by administering the pharmaceutical compositions of the invention are also disclosed.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: November 7, 2017
    Assignee: Cognosci, Inc.
    Inventors: Michael P. Vitek, Dale J. Christensen
  • Patent number: 9809641
    Abstract: The present invention aims to provide a lactoferrin fusion protein, which is configured to retain the biological activities of natural lactoferrin, to have a significantly prolonged in vivo lifetime, and to be more clinically useful than natural and gene recombinant lactoferrin, as well as a method for preparation thereof, etc. The present invention provides a fusion protein formed with a protein or peptide comprising an FcRn-binding region and lactoferrin or a biologically active fragment or peptide of lactoferrin, which is represented by: (LF-s-Y)n or (Y-s-LF)n [wherein LF represents lactoferrin or a biologically active fragment or peptide of lactoferrin, represents the protein or peptide comprising an FcRn-binding region, s represents ally amino acid sequence of 0 to 10 residues, and n represents an integer of 1 to 10], or a variant thereof.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: November 7, 2017
    Assignee: NRL PHARMA, INC.
    Inventors: Atsushi Sato, Shinji Kagaya
  • Patent number: 9809642
    Abstract: A transgenic chicken comprising an inactivated heavy immunoglobulin gene and/or inactivated light chain immunoglobulin gene is provided, as well as cells and targeting vectors for making the same.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: November 7, 2017
    Assignee: Crystal Bioscience Inc.
    Inventors: Philip A. Leighton, William Don Harriman, Robert Etches
  • Patent number: 9809643
    Abstract: Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as RABV, MOKV and WCBV) and/or specifically bind recombinant glycoprotein from different lyssaviruses.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: November 7, 2017
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Todd G. Smith, Xianfu Wu
  • Patent number: 9809644
    Abstract: Antibodies against influenza hemagglutinin, compositions containing the antibodies, and methods of using the antibodies are provided herein.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: November 7, 2017
    Assignee: iBio Inc.
    Inventors: Vidadi Yusibov, Vadim Mett, Jessica Chichester, Lauren Goldschmidt
  • Patent number: 9809645
    Abstract: [Problem] The present invention addresses the problem of providing an anti-Staphylococcus antibody having preventive or therapeutic effects on staphylococcal infections. [Solution] Provided is an anti-Staphylococcus antibody having preventive or therapeutic effects on staphylococcal infections and a method for manufacturing said antibody, as well as a composition, a product, and a drug containing said antibody. The antibody is obtained by using deacetylated Staphylococcus for immunization.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: November 7, 2017
    Assignees: ZENYAKU KOGYO KABUSHIKIKAISHA, Juntendo Educational Foundation
    Inventors: Hiroyoshi Ohsawa, Jumpei Enami, Keiichi Hiramatsu
  • Patent number: 9809646
    Abstract: The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific CDR sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. More preferably, the antibodies or fragments also comprise specific constant region sequences, such as those associated with the nG1m1,2 or Km3 allotypes. The antibodies or fragments may bind to a human histone protein, such as H2B, H3 or H4. The antibodies or fragments are of use to treat a variety of diseases that may be associated with histones, such as autoimmune disease (e.g.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: November 7, 2017
    Inventors: Chien-Hsing Chang, Hans J. Hansen, David M. Goldenberg
  • Patent number: 9809647
    Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: November 7, 2017
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Toshio Imai, James Bradford Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
  • Patent number: 9809648
    Abstract: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: November 7, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Leonard G. Presta, Brian M. Beyer, Richard N. Ingram, Peter Orth, Yan-Hui Liu
  • Patent number: 9809649
    Abstract: Administration of an antibody that specifically binds IL-1? is useful for treating cachexia and increasing the lifespan of a subject suffering from cachexia.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: November 7, 2017
    Assignee: XBIOTECH, INC.
    Inventor: John Simard
  • Patent number: 9809651
    Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: November 7, 2017
    Assignee: BIOCON LIMITED
    Inventors: Nagaraj Govindappa, Kedarnath Sastry, Maria Melina Soares
  • Patent number: 9809652
    Abstract: The present disclosure relates to methods of treating individuals suffering from progressive forms of multiple sclerosis.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: November 7, 2017
    Assignees: AbbVie Biotherapeutics Inc., Biogen MA Inc.
    Inventors: Steven Jay Greenberg, Jacob Stephen Broomall Elkins
  • Patent number: 9809653
    Abstract: Antibodies are provided which specifically bind human and Macaca fascicularis lysosomal-associated membrane protein 1 (LAMP1) proteins and immunoconjugates comprising said antibodies conjugated or linked to a growth inhibitory agent. Pharmaceutical compositions comprising antibodies or immunoconjugates of the invention and use of the antibodies or immunoconjugates for the treatment of cancer are also provided, as well as LAMP1 antibodies, isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies and the use of said antibody as a diagnostic tool. The application further provides for the detection of LAMP1 gene amplification or gain in cancer cells leading to the determination if patients with cancer are likely to respond to anti-LAMP1 therapy. Anti-LAMP1 therapeutic agent for use for treating cancer in a patient harboring LAMP1 gene copy number gain in cancer cells is further provided.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: November 7, 2017
    Assignee: SANOFI
    Inventors: Yves Baudat, Francis Blanche, Béatrice Cameron, Tarik Dabdoubi, Anne-Marie LeFebvre, Magali Mathieu, Ana Merino-Trigo, Manoel Nunes
  • Patent number: 9809654
    Abstract: The invention is directed to a compound comprising one or more CD1d complexes in association with an antibody specific for a cell surface marker. The CD1d complexes comprise a CD1d, a ?2-microglobulin molecule, and may further comprise an antigen bound to the CD1d binding groove. The invention is further directed to methods of inhibiting or stimulating an immune response with the CD1d-antibody compounds, in particular anti-tumor and autoimmunity responses.
    Type: Grant
    Filed: September 26, 2003
    Date of Patent: November 7, 2017
    Assignee: Vaccinex, Inc.
    Inventors: Bruno Robert, Alena Donda, Valerie Cesson, Jean-Pierre Mach, Maurice Zauderer
  • Patent number: 9809655
    Abstract: The invention relates to a method for modifying nanofibrillar cellulose composition, comprising—preparing fibrous dispersion of ionically charged nanofibrillar cellulose (NFC), and—applying heat treatment at a temperature of at least 90° C. to the fibrous dispersion until the viscosity of NFC starts to decrease. The viscosity of the heat-treated NFC is reversible by applying shear forces to the NFC.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: November 7, 2017
    Assignee: UPM-KYMMENE CORPORATION
    Inventors: Antti Laukkanen, Markus Nuopponen, Martina Lille
  • Patent number: 9809656
    Abstract: Processes for making and using a viscosified liquid slurry polymerization additive are disclosed herein. The process for making a viscosified liquid slurry polymerization additive comprises contacting a polymerization additive with a liquid to form a liquid slurry polymerization additive, and shearing the liquid slurry polymerization additive to increase its viscosity and thus form the viscosified liquid slurry polymerization additive. The process for using a viscosified liquid slurry polymerization additive comprises contacting, under polymerization conditions, in a reactor system: a catalyst system, one or more monomers, and at least one viscosified liquid slurry polymerization additive.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: November 7, 2017
    Assignee: Univation Technologies, LLC
    Inventors: Richard B. Pannell, David M. Glowczwski, Chi-I Kuo
  • Patent number: 9809657
    Abstract: A solution of a mixed alkaline earth alkoxide compound with an aluminum compound in an aprotic solvent, and methods of making and using them.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: November 7, 2017
    Assignee: ALBEMARLE GERMANY GMBH
    Inventors: Ulrich Wietelmann, Armin Stoll, Florian Kiefer, Ute Emmel
  • Patent number: 9809658
    Abstract: Described herein is a method of purifying a product and recycling water comprising the following steps: (i) providing a crude product comprising at least one low molecular weight fluoroorganic compounds wherein the low molecular weight fluoroorganic compounds is partially fluorinated and comprises a polar group and/or a reactive group; (ii) extracting the impurity from the product using water to form an extract, (iii) contacting the extract with a radical-forming process to degrade the low molecular weight fluoroorganic compounds into carbon dioxide, water, fluorine ions, and optionally cations; and (iv) using the water from step (iii) in step (ii)
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: November 7, 2017
    Assignee: 3M Innovative Properties Company
    Inventors: Klaus Hintzer, Michael Juergens, Gunther J. Kaempf, Harald Kaspar, Kai H. Lochhaas, Andre Streiter, Oleg Shyshkov, Tilman C. Zipplies, Herbert Koenigsmann
  • Patent number: 9809659
    Abstract: A process for the preparation of polyethylene by polymerizing in a slurry ethylene and optionally one or more C3 to C10 alpha-olefins in a reactor system comprising a polymerization reactor and one or more first heat exchangers located outside the polymerization reactor where the slurry in the polymerization reactor is cooled by withdrawing slurry from the polymerization reactor, cooling the slurry in the one or more first heat exchangers and returning the cooled slurry to the polymerization reactor, wherein the one or more first heat exchangers are cooled by a first coolant having a temperature of 29° C. or higher.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: November 7, 2017
    Assignee: Basell Polyolefine GmbH
    Inventors: Giuseppe Penzo, Rodrigo Carvajal, Reinhard Kuehl, Elke Damm
  • Patent number: 9809660
    Abstract: A process for making a low density polymer in a polymerization reactor system, the process comprising polymerizing an olefin monomer, and optionally an olefin comonomer, in the presence of a diluent in a polymerization reactor to make a polymerization product slurry consisting of a liquid phase and a solid phase, wherein the solid phase comprises an olefin polymer having a density of between about 0.905 g/cm3 to about 0.945 g/cm3; and discharging the polymerization product slurry from the polymerization reactor through a continuous take-off valve to make a mixture further comprising a vapor phase. The mixture comprises a pressure less than a bubble point pressure of a component in the polymerization product slurry.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: November 7, 2017
    Assignee: Chevron Phillips Chemical Company, LP
    Inventors: John D. Hottovy, Scott E. Kufeld, Joel A. Mutchler
  • Patent number: 9809661
    Abstract: A process for the continuous synthesis of diene elastomers with a high degree of conversion is provided. The process includes simultaneously: a) introducing continuously into a polymerization reactor containing a gas phase and equipped with at least one stirring rotor and a discharge device, at least i. one or more monomers, including at least one conjugated diene monomer, and ii. from 0% to 70% by mass of an organic solvent, calculated relative to the total mass of monomers and of solvent b) continuously polymerizing the monomer(s), c) stirring the polymerization medium via the continuous movement of at least one stirring rotor about a rotary axle, d) continuously discharging the elastomer paste, e) continuously conveying the discharged elastomer paste to a chopping device and chopping it into particles, f) removing solvent from the particles of the elastomer paste, and g) recovering diene elastomer.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: November 7, 2017
    Assignees: COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN, MICHELIN RECHERCHE ET TECHNIQUE S.A.
    Inventors: Jerome Dussillols, Pierre Kiener, Helene Parola
  • Patent number: 9809662
    Abstract: Processes for producing a polypropylene product by using a lower purity propylene stream. An operating parameter of the separation zone for a dehydrogenation zone effluent may be adjusted or controlled to lower the purity of the propylene stream produced by the separation zone. The reflux rate of propylene-propane splitter may be reduced. The duty of the reboiler for the propylene-propane splitter may be lowered. The number of stages in the propylene-propane splitter may be decreased.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: November 7, 2017
    Assignee: UOP LLC
    Inventors: Adam J. Kanyuh, Michael J. Banach, Robert B. James
  • Patent number: 9809663
    Abstract: The present invention provides a catalyst component for olefin polymerization and a preparation method thereof, and a catalyst for olefin polymerization and an application thereof. The catalyst component for olefin polymerization comprises reaction products of the following components: (1) a solid component; (2) at least one titanium compound; and (3) at least two internal electron donors, wherein the solid component comprises a magnesium compound represented by formula (1) and an epoxide represented by formula (2), wherein R1 is a C1-C12 linear or branched alkyl; R2 and R3 are identical or different, and are independently hydrogen or unsubstituted or halogen-substituted C1-C5 linear or branched alkyl; X is halogen; m is in a range of from 0.1 to 1.9, n is in a range of from 0.1 to 1.9, and m+n=2.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: November 7, 2017
    Assignees: CHINA PETROLEUM & CHEMICAL CORPORATION, BEIJING REAEARCH INSTITUTE OF CHEMICAL INDUSTRY, CHINA PETROLEUM & CHEMICAL CORPORATION
    Inventors: Xianzhi Xia, Jin Zhao, Weili Li, Yuexiang Liu, Yongtai Ling, Ping Gao, Yang Tan, Futang Gao, Renqi Peng, Jigui Zhang
  • Patent number: 9809664
    Abstract: This invention relates to high porosity (?15%) and/or low pore diameter (PD<165 ?m) propylene polymers and propylene polymerization processes using single site catalyst systems with supports having high surface area (SA?400 m2/g), low pore volume (PV?2 mL/g), a specific mean pore diameter range (PD=1-20 nm), and high average particle size (PS?30 ?m).
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: November 7, 2017
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: Luo Lubin, Matthew W. Holtcamp, Gregory S. Day
  • Patent number: 9809665
    Abstract: A process for production of polyisobutylene includes subjecting a reaction admixture comprising isobutylene, a diluent for the isobutylene, which may be isobutane, and a catalyst composition, that may include a BF3/methanol catalyst complex, to reaction conditions suitable for causing at least a portion of the isobutylene to undergo polymerization to form a polyisobutylene product including polyisobutylene molecules. At least a fraction of the polyisobutylene molecules thus produced have alpha position double bonds and the polyisobutylene product has a number average molecular weight (MN) and a polydispersity index (PDI). The concentration of the diluent in the reaction admixture may be manipulated to control or change any one or more of (a) the relative size of the fraction, (b) the number average molecular weight of the product, (c) the polydispersity index of the product and (d) the relative size of the portion.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: November 7, 2017
    Assignee: TPC GROUP LLC
    Inventors: Klaus R. Menschig, Sohel Shaikh, Sathy R. Ponnuswamy, Rex Lawson
  • Patent number: 9809666
    Abstract: The present invention relates to a polypropylene composition comprising a multimodal propylene random copolymer with at least one comonomer selected from alpha-olefins with 2 or 4 to 8 carbon atoms, wherein the polypropylene composition has a melt flow rate MFR2 (2.16 kg, 230° C.) of 0.05 to 1.0 g/10 min, determined according to ISO 1133, a polydispersity index (PI) of 2.0 to 7.0, and a Charpy Notched Impact Strength at 0° C. of more than 4.0 kJ/m2, determined according to ISO 179/1eA:2000 using notched injection moulded specimens, a process for producing said polypropylene composition, an article comprising said polypropylene composition and the use of said polypropylene composition for the production of an article.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: November 7, 2017
    Assignees: ABU DHABI POLYMERS COMPANY LIMITED (BOROUGE), BOREALIS AG
    Inventors: Cristian Hedesiu, Kauno Alastalo